S-Adenosyl-Methionine
Phase 2Small molecule
S-Adenosyl-Methionine is one of 95 small molecule programs targeting Abdominal pain. It is currently in Phase 2.
3
Indications
5
Total Trials
0
Active Trials
94
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
797 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1S-Adenosyl-Methionine
NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2
Cysteine Hydrochloride
NovartisPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Vermox
WWim Janssens
Preclinical
Opdivo
Bristol-Myers SquibbPreclinical
Statin
Bristol-Myers SquibbPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma2 trials
Abdominal pain1 trial
Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children
Completed·—·N/A·NCT00694564·8 enrolled
Hepatic Carcinoma1 trial
Cirrhosis1 trial
SAMe to Treat Biliary Cirrhosis Symptoms
Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00125281·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S-Adenosyl-Methionine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details